4-Phenyl-pyridine compound

Abstract

The present invention relates to compound of the general formula wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R1 is hydrogen or halogen; or R and R1 maybe together -CH=CH CH=CH-; R2 and R2' are independently from each other hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; or R2 and R2' may be together -CH=CH CH=CH-, optionally substituted by one or two substituents selected from lower alkyl or lower alkoxy; R3 is hydrogen, lower alkyl or form a cyclOalkyl group; R4 is hydrogen, -N(R5)2' N(R5)(CH2)nOH, -N(R5)S(O)2-lower alkyl, -N(R5)S(O)2- phenyl, -N=CH N(R5)2' -N(R5)C(O)Rs or a cyclic tertiary amine of the group as annexed R5 is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl; R6 is hydrogen, hydroxy, lower alkyl, (CH2)nCOO-lower alkyl, -N(R5)CO lower 20 alkyl, hydroxy-lower alkyl, cyano, -(CH2)nO(CH2)nOH, -CHO or as-5-or 6 membered heterocyclic group, optionally bonded via an alkylene group, X is —C(O)N(R5)-, -(CH2)mO-, (CH2)mN(R5)-, -N(R5)C(O)-, or — N(R5)(CH2)m-; n is 0 - 4; and m is 1 or 2; and the compound of formula I show a high affinity to the NK- 1 receptor. It may be used for the treatment of diseases, which relate to NK-1 receptor antagonists.